# A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants

> **NCT04316585** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 29 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** GSK2982772
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04316585
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-28
- **Primary completion:** 2021-09-13
- **Final completion:** 2021-10-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04316585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04316585, "A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04316585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*